Loading
LAG-3 blockers helped in measurable melanoma with one drug pairing, but failed as adjuvant therapy and with a different PD-1 partner.
This caution notes that LAG-3 blockade in melanoma has succeeded in only one setting: relatlimab with nivolumab in unresectable, measurable disease, as shown in RELATIVITY-047. The same pairing failed as adjuvant therapy in RELATIVITY-098, and the alternative LAG-3 antibody fianlimab with cemiplimab failed in a first-line phase 3 reported in 2026. LAG-3 is expressed on exhausted T cells inside tumours, so without tumour present, or with different antibody properties and comparators, the effect may vanish. Two negative phase 3 trials against one positive one mean the benefit cannot be assumed to transfer to the adjuvant setting or to a different PD-1 partner.
Shares RELATIVITY-098, RELATIVITY-047, Relatlimab + nivolumab, LAG-3.
Shares Fianlimab, Relatlimab + nivolumab, Melanoma.
Shares RELATIVITY-047, Relatlimab + nivolumab, LAG-3, Melanoma.
Shares Relatlimab + nivolumab, Melanoma.
Shares Relatlimab + nivolumab, LAG-3.
Shares Relatlimab + nivolumab, Melanoma.
Shares Relatlimab + nivolumab, Melanoma.